4D pharma PLC (AIM:DDDD, NASDAQ:LBPS)'s Chief Executive Officer Duncan Peyton joins Proactive London about hitting their primary efficacy target in a phase I/II trail of one of its lead assets in kidney cancer.
MRx0518 was used in a combination with KEYTRUDA, the Merck blockbuster, which is part of a class of drugs called immune checkpoint inhibitors.
The ongoing study is being conducted in heavily pre-treated metastatic patients with solid tumours who have previously experience clinical benefit on prior ICI therapy and subsequently developed progressive disease.